Avanos Medical AI Price Prediction

The negative EPS of -10.18 and a corresponding negative PE ratio of -1.21 indicate that Avanos Medical is currently unprofitable. This points to significant earnings pressure and likely one-time or ongoing charges that are weighing on the bottom line. Without evidence of a clear path back to sustained profitability, the financial profile leans negative for equity holders.

• Negative EPS of -10.18 suggests material net losses, implying that current operations and/or restructuring/impairment charges are substantially impacting earnings.
• A PE ratio of -1.21 confirms that the stock is not generating positive earnings, which typically constrains valuation support and can increase volatility.
• Lack of positive profitability metrics (e.g., no indication of improving margins or earnings inflection) makes it difficult to justify a strong upside case based purely on fundamentals.

Alternative data for Avanos Medical is mixed but leans negative. Web traffic of roughly 38,160 visitors per month is modest for a public medtech company, and job openings have declined 22.6% month over month, which can signal hiring caution or cost-cutting. Social media followings are growing slowly from relatively low bases, suggesting limited brand engagement momentum.

• Job openings at 48, down 22.6% month over month, may indicate reduced growth investment, hiring freezes, or cost-control measures, which often align with financial pressure or strategic retrenchment.
• Estimated monthly web traffic of 38,160 visitors appears modest and there is no indication of strong growth, limiting evidence of accelerating commercial interest or demand.
• Social media audiences are small to moderate (e.g., 592 on Twitter/X, 915 on Instagram, 19,260 on Facebook, 2,130 on YouTube, 62,651 on LinkedIn) with only low single-digit percentage growth over 90 days, pointing to incremental rather than robust engagement expansion.

Combining negative earnings, modest technical strength, and soft alternative data, the overall picture for Avanos Medical currently skews bearish. While the stock trades slightly above its 200-day moving average and has risen in the last month, the lack of profitability and signals of cautious hiring and only tepid engagement limit conviction in a sustained upside move.

• Unprofitable operations, reflected in a deeply negative EPS and negative PE ratio, are the dominant factor and weigh heavily on the equity case.
• Mildly constructive technicals and small gains in social and web presence are not strong enough to offset concerns from weak earnings and reduced hiring activity.